Puzzle Financial Advice

How long after second dose of AstraZeneca vaccine, before it is effective?  9/6/21

• https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/is-it-true/is-it-true-how-long-does-it-take-to-have-immunity-after-vaccination   9/June/21

• "Individuals may not have the best protection until 7-14days after their second dose of the vaccine."

 

 

Concerns about AstraZeneca vaccine: My alarm was raised when I first understood from Anne de Gheest's 2nd April 2021 that the AstraZeneca vaccine was not very effective against the South African and the Brazilian variants of COVID. So this page seeks to monitor developments in "that space".

​

https://en.wikipedia.org/wiki/Oxford%E2%80%93AstraZeneca_COVID-19_vaccine

• At 18/Apr/21, this web page says:-

  • https://en.wikipedia.org/wiki/Oxford%E2%80%93AstraZeneca_COVID-19_vaccine#New_variant_efficacy

    • "concern arose that the E484K mutation, present in the South African (B.1.351) and Brazilian (B.1.1.28) variants, could evade the protection given by the (AstraZeneca) vaccine".

    • 'In February 2021, the collaboration was working to adapt the vaccine to target these variants, with the expectation that a modified vaccine would be available "in a few months" as a "booster" given to people who had already completed the two-dose series of the original vaccine'. 8/Feb/2021  https://www.cnbc.com/2021/02/08/astrazeneca-races-to-adapt-covid-vaccine-as-south-africa-halts-rollout.html

• "3 doses, then 1 each year: why Pfizer, not AstraZeneca, is the best bet for the long haul"  20/Apr/21

  • https://theconversation.com/3-doses-then-1-each-year-why-pfizer-not-astrazeneca-is-the-best-bet-for-the-long-haul-159137   

  • This article largely comes to the same conclusions as I have.

• https://en.wikipedia.org/wiki/Lineage_B.1.351#Oxford%E2%80%93AstraZeneca_(AZD1222)

  • "On 6 February 2021, The Financial Times reported that provisional trial data from a study undertaken by South Africa's University of the Witwatersrand in conjunction with Oxford University demonstrated reduced efficacy of the Oxford–AstraZeneca COVID-19 vaccine against the 501.V2 variant. The study found that in a sample size of 2,000 the AZD1222 vaccine afforded only "minimal protection" in all but the most severe cases of COVID-19."

    • https://en.wikipedia.org/wiki/Lineage_B.1.351#cite_note-85

      • Booth, William; Johnson, Carolyn Y. (7 February 2021). "South Africa suspends Oxford-AstraZeneca vaccine rollout after researchers report 'minimal' protection against coronavirus variant". The Washington Post. London. Retrieved 8 February 2021. South Africa will suspend use of the coronavirus vaccine being developed by Oxford University and AstraZeneca after researchers found it provided "minimal protection" against mild to moderate coronavirus infections caused by the new variant first detected in that country.

​

​